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Prognosis for FLT3-ITD positive acute myeloid leukemia with highallelic ratio (>0.5) is poor, particularly in relapse, refractory to orunfit for intensive treatment, thus highlighting an unmet need for
novel therapeutic approaches. The combined use of compounds target-
ing both the mutated FLT3 receptor and cellular p53 inhibitors might be
a promising treatment option for this poor risk leukemia subset. We
therefore assessed MDM2 and FLT3 inhibitors as well as cytotoxic com-
pounds used for conventional induction treatment as single agents and
in combination for their ability to induce apoptosis and cell death in
leukemic cells. Acute myeloid leukemia cells represented all major mor-
phologic and molecular subtypes with normal karyotype, including
FLT3-ITD (>0.5) and FLT3 wild type, NPM1 mutant and NPM1 wild
type, as well as TP53 mutant and TP53 wild type cell lines. Acute
myeloid leukemia cells with mutated or deleted TP53 were resistant to
MDM2- and FLT3-inhibitors. FLT3-ITD positive TP53 wild type acute
myeloid leukemia cells were significantly more susceptible to 
FLT3-inhibitors than FLT3-ITD negative TP53 wild type cells. The pres-
ence of a NPM1 mutation reduced the susceptibility of TP53 wild type
acute myeloid leukemia cells to the MDM2 inhibitor NVP-HDM201.
Moreover, the combined use of MDM2- and FLT3-inhibitors was supe-
rior to single agent treatment, and the combination of midostaurin and
NVP-HDM201 was as specific and effective against FLT3-ITD positive
TP53 wild type cells as the combination of midostaurin with conven-
tional induction therapy. In summary, the combined use of the MDM2
inhibitor NVP-HDM201 and the FLT3 inhibitor midostaurin was a most
effective and specific treatment to target TP53 and NPM1 wild type
acute myeloid leukemia cells with high allelic FLT3-ITD ratio. These
data suggest that the combined use of NVP-HDM201 and midostaurin
might be a promising treatment option particularly in FLT3-ITD positive
acute myeloid leukemia relapsed or refractory to conventional therapy.  
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ABSTRACT
Introduction
Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized
by blocked differentiation and deregulated proliferation of hematopoietic precur-
sor cells. At the cellular level, specific genetic and epigenetic alterations lead to
changes in cellular signaling pathways including the common inactivation of the
p53 tumor suppressor axis, and thereby contribute to blocked differentiation and
accumulation of leukemic blasts in the blood and the bone marrow. The past
decade has witnessed major advances in our comprehension of the biologic hetero-
geneity of AML.1 AML genetic variants are assigned into favorable, intermediate
and poor risk categories, and a major molecular subgroup within the poor risk AML
is characterized by genetic alterations of the FLT3 receptor gene. FLT3 internal tan-
dem duplications (FLT3-ITD) are the most common muta-
tions in the FLT3 receptor gene. FLT3-mutated AML
account for 25-35% of all AML, and their prognosis is
poor, particularly in unfit, refractory or relapsed patients. 
Targeting the mutated FLT3 receptor is a promising
approach to treat this specific AML subset. Midostaurin
(PKC412) is a first generation type III receptor tyrosine
kinase inhibitor that has been extensively studied in vitro
and in clinical trials as a treatment for AML patients with
mutated FLT3.2,3 After successful phase II clinical trials,
midostaurin was found to significantly prolong survival of
FLT3-mutated AML patients when combined with con-
ventional induction and consolidation therapies in a ran-
domized phase III clinical trial leading to the first new
drug approval in AML in over 40 years.4 Midostaurin is a
multi-targeted kinase inhibitor able to block FLT3 auto-
phosphorylation and to induce growth arrest and apopto-
sis in FLT3-dependent leukemia.5 Midostaurin is orally
administered and generally well tolerated as a single
agent. Quizartinib (ACC220) and gilteritinib (ASP2215)
are second and third generation FLT3 inhibitors currently
in evaluation for the treatment of FLT3-mutated AML.6-8
Targeting the p53 antagonist MDM2 is a novel approach
to restore the crucial p53 tumor suppressor function in
AML cells.9 Idasanutlin (RG7833) is a second generation
MDM2 inhibitor that has been studied in vitro and in vivo
as a treatment for AML patients with wild type TP53.10
NVP-CGM09711 and NVP-HDM20112 are second genera-
tion MDM2 inhibitors that are currently evaluated in sin-
gle-agent phase I studies in patients with advanced tumors
with wild type TP53 (clinicaltrials.gov identifiers 01760525
and 02143635). Like midostaurin, NVP-HDM201 is orally
administered and expected to be well tolerated as single
agent. 
In this study, we investigated the combined treatment
with MDM2- and FLT3- inhibitors, in particular NVP-
HDM201 and midostaurin, on AML cells in order to iden-
tify a potentially effective treatment specifically for 
FLT3-ITD AML refractory to or unfit for intensive
chemotherapy. The study might provide the rationale for
initiating a clinical study in FLT3-ITD AML evaluating this
combination.
Methods
Patient samples
Mononuclear cells of AML patients diagnosed and treated at the
University Hospital, Bern, Switzerland between 2005 and 2015
were included in this study. Informed consent from all patients
was obtained according to the Declaration of Helsinki, and the
studies were approved by decisions of the local ethics committee
of Bern, Switzerland. Mutational screening for FLT3, NPM1, TP53
and conventional karyotype analysis of at least 20 metaphases
were performed for each patient. Peripheral blood mononuclear
cells (PBMCs) and bone marrow mononuclear cells (BMMCs)
were collected at the time of diagnosis before initiation of treat-
ment. 
AML cell lines
OCI-AML2 (AML-M4, FLT3wt, DNMT3A R882C, NPM1wt,
TP53wt); OCI-AML3 (AML-M4, FLT3wt, DNMT3A R882C,
NPM1mut, TP53wt), MOLM-13 (AML-M5, t(9;11), FLT3-ITD,
TP53wt), MOLM-16 (AML-M0, FLT3wt, TP53mut), MV4-11
(AML-M5, t(4;11), FLT3-ITD, TP53wt), ML-2 (AML-M4, t(6;11),
FLT3wt, TP53mut), PL-21 (AML-M3, FLT3wt, TP53hemi) and
HL-60 (AML-M2, FLT3wt, TP53null) cells were supplied by the
Leibniz Institute DSMZ, German Collection of Microorganisms
and Cell Cultures. AML cells were grown in RPMI 1640
(SIGMA-ALDRICH, St. Louis, MO, USA) supplemented with
20% fetal bovine serum (FBS, Biochrom GmbH, Germany). 
Cytotoxicity assays
AML cells were treated with the MDM2 inhibitors NVP-
HDM201, NVP-CGM097, idasanutlin (RG7388), the FLT3
inhibitors midostaurin (PKC412), quizartinib (ACC220), gilteri-
tinib (ASP2215) or with genotoxic compounds cytarabine and
idarubicin in equimolar concentrations. NVP-HDM201 and
NVP-CGM097 investigational compounds were supplied by
Novartis, Switzerland, whereas RG7833, PKC412, ACC220 and
ASP2215 were purchased at MCE (MedChemExpress,
Monmouth Junction, NJ, USA). Cytarabine and idarubicin were
purchased at Sigma-Aldrich (St.Louis, MO, USA) and
SelleckChem (Houston, TX, USA).  Cell viability was deter-
mined using the MTT-based in vitro toxicology assay (TOX1,
Sigma-Aldrich) with four repeat measurements per dosage. Data
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Table 1. Genetic variants in AML cell lines.
ID FLT3 TP53 NPM1 mutated genes
HL-60 wt del wt NRAS Q61L
CDKN2A R80X
MOLM-13 ITD wt wt MLL-AF9 (t9;11)
MOLM-16 wt V173M C238S wt MLL V1368L
MTOR T571K
MV4-11 ITD wt wt MLL-ENL (t4;11)
OCI-AML2 wt wt wt DNMT3A R635W
A680V MLL K1751*
OCI-AML3 wt wt L287fs DNMT3A R882C
NRAS Q61L
PL-21 wt wt wt KRAS A146V
P336L P36fs
wt: wild type; ITD: internal tandem duplication; del: deletion  
are depicted as XY graphs with median and interquartile range,
as box plots or scatter plots with mean values. Statistical analy-
sis was done on GraphPad Prism (version 7, GraphPad software,
LaJolla, CA, USA) in grouped analysis and significance calculat-
ed by Mann-Whitney test. Combination indexes were calculat-
ed on CompuSyn software (version 1.0; ComboSyn, Inc.
Paramus, NJ,USA).
Measurement of mRNA expression by qPCR
RNA was extracted from AML cells and quantified using qPCR.
The RNA extraction kit was supplied by Macherey-Nagel, Düren,
Germany. Reverse transcription was done with MMLV-RT
(Promega, Madison, WI, USA). Real-time PCR was performed on
the ABI7500 Real-Time PCR Instrument using ABI universal mas-
ter mix (Applied Biosystems, Austin, TX, USA) and gene specific
probes Hs00355782_m1 (CDKN1A), Hs01050896_m1  (MCL1)
and Hs02758991_g1 (GAPDH) (ThermoFischer Scientific,
Waltham, MA, USA). Measurements of CDKN1A and MCL1
expression were normalized with GAPDH values (ddCt relative
quantitation).  Assays were performed in three or more independ-
K. Seipel et al.
1864 haematologica | 2018; 103(11)
Figure 1. Variable responses of AML cell lines to FLT3 and MDM2 inhibitors. Dose response curves in AML cell lines treated with FLT3 inhibitors (A,B,C) and MDM2
inhibitors (D,E,F) as single compound treatment with midostaurin (PKC412) (A), quizartinib (AC220) (B), gilteritinib (ASP2215) (C), idasanutlin (RG7833) (D), NVP-
CGM097 (E) or NVP-HDM201 (F), in a variety of AML cell lines (G) and combination treatments with NVP-HDM201 and PKC412, ACC220 or ASP2215 in MOLM-13
cells (H). Combination indexes were calculated according to Chou Talalay.42
A B C
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ent experiments. Statistical analysis was done on GraphPad Prism
software using two-tailed t-tests (version 7, GraphPad software,
LaJolla, CA, USA). Data are depicted in column bar graphs plotting
mean with SD values. 
Antibodies and cytometry
Staining for apoptosis was done using AnnexinV-CF488A
(Biotium, Germany) in AnnexinV buffer and Hoechst 33342 
(10 mg/ml) for 15 min. at 37C, followed by several washes.
Propidium iodide was added shortly before imaging on the
Nucleocounter NC-3000 (ChemoMetec, Allerod, Denmark).
For cell cycle analysis cells were incubated in lysis buffer with
DAPI (10 mg/ml) for 5 min. at 37°C and analyzed on NC-3000
imager. 
Results
Sensitivity of AML cell lines to MDM2 and FLT3
inhibitors
To determine the sensitivity of AML cells to MDM2 and
FLT3 inhibitors, AML cell lines were treated with three
MDM2- and three FLT3-inhibitors for 24 hours in dose
escalation experiments before cell viability assessment.
The AML cell lines covered the major morphologic and
molecular subtypes including particularly FLT3-ITD and
FLT3 wild type, NPM1 mutant and wild type, as well as
TP53 wild type, mutant, hemizygous and null cells (Table
I). The two FLT3-ITD cell lines MV4-11 and MOLM-13
had high allelic ratios of FLT3-ITD and chromosomal
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Figure 2. Variable responses of AML blast cells to midostaurin and HDM201. Cell viability was determined in AML patient cells treated with midostaurin (PKC412)
(A) or NVP-HDM201 (B). AML cells were grouped according to major molecular subtypes (FLT3/TP53/NPM1).  Cell viability measurements are depicted in dose
response curves (A, B) or with 50nM single compound (C, D), as well as combination treatment of midostaurin with conventional induction therapy (E) or midostaurin
with NVP-HDM201 (F). PBM are peripheral blood monocytes of normal controls. AML patient samples were analyzed in groups of at least four individual samples
(Online Supplementary Table S1) using GraphPad prism software. Significance is denoted for P<0.05 (*); P<0.005 (**); P<0.0005 (***); P<0.0001 (****); P>0.05
(ns). 
translocations with MLL gene rearrangements. Some cell
lines contained additional mutations in driver genes such
as DNMT3A (OCI-AML2, OCI-AML3) and RAS genes
(OCI-AML3, PL-21). DNMT3a and RAS gene mutations
may influence sensitivity to MDM2 or FLT3 inhibitors.
The MDM2 inhibitors included idasanutlin (RG7388),
NVP-CGM097 and NVP-HDM201. The FLT3 inhibitors
included the 1st, 2nd and 3rd generation inhibitors midostau-
rin (PKC412), quizartinib (ACC220) and gilteritinib
(ASP2215). The FLT3-ITD positive and TP53 wild type cell
lines MOLM-13 and MV4-11 were most susceptible to all
three FLT3- and all three MDM2-inhibitors (Figure 1). The
effects on MOLM-13 cell survival induced by the three
FLT3 inhibitors were consistent with IC50 values of
200nM (Figure 1A,B,C). Quizartinib had a greater potency
with 70% cell viability after treatment with 10nM com-
pound, while midostaurin and gilteritinib had comparable
potencies with 90% cell viability at 10nM compound.
OCI-AML2 and PL-21 cells showed some response to
midostaurin while OCI-AML3, MOLM-16 and HL-60
cells were rather resistant to midostaurin and quizartinib.
With respect to gilteritinib, however, OCI-AML3, PL-21
and HL-60 cells showed some response and only MOLM-
16 cells were resistant. The effects on MOLM-13 cell sur-
vival varied for the MDM2 inhibitors with IC50 values of
300nM NVP-HDM201, 1 mM RG7388 and 10 mM NVP-
CGM097 (Figure 1D,E,F). MOLM-13 cells were most sus-
ceptible to MDM2 inhibitor idasanutlin with IC50 at 1 mM
RG7388. MV4-11 and OCI-AML2 cells showed some
response to idasanutlin with IC50 of 10 mM RG7388 while
OCI-AML3, PL-21, HL-60 and MOLM-16 cells were
rather resistant to idasanutlin. With respect to the MDM2
inhibitors NVP-CGM097 and NVP-HDM201 MOLM-13,
MV4-11 and OCI-AML2 cells showed consistent suscepti-
ble responses while OCI-AML3 and PL-21 cells were less
susceptible and MOLM-16 and HL60 cells were resistant.
In order to define the most effective treatment combina-
tion we focused our studies on the latest and most potent
MDM2 inhibitor NVP-HDM201 and tested its effects in
single agent treatment and together with the three FLT3-
inhibitor compounds in MOLM-13 cells. The combination
of NVP-HDM201 and midostaurin had excellent synergis-
tic effects on cell survival with a combination index of 0.4,
while the combination of NVP-HDM201 with quizartinib
or gilteritinib had only moderate synergistic effects with
combination indexes of 0.7 and 0.8 (Figure 1H). To deter-
mine the relevance of the order of addition, midostaurin
and NVP-HDM201 were tested as direct combination or
sequential treatment and found to be effective independ-
ent of sequence of application. NVP-HDM201 pretreat-
ment followed by midostaurin treatment had similar
effects on cell viability as midostaurin pretreatment fol-
lowed by NVP-HDM201 treatment. Moreover, both
sequential treatments had comparable effects on cell via-
bility as direct combination treatment (Online
Supplementary Figure S1).
Sensitivity of AML patient cells to the MDM2 inhibitor
HDM201 and the FLT3 inhibitor midostaurin
To determine the sensitivity of NK-AML blast cells to
HDM201 and midostaurin, mononuclear cells isolated
from peripheral blood or bone marrow of NK-AML
patients were subjected to in vitro cytotoxicity assays. The
NK-AML cells covered the major morphologic and molec-
ular subtypes including FLT3-ITD and FLT3 wild type,
NPM1 mutant and wild type, as well as TP53 mutant and
wild type cells (Online Supplementary Table S1). Most of the
FLT3-ITD AML cells had a high allelic ratio of FLT3-ITD
(>0.5). Only few of the patient samples contained addi-
tional mutations in driver genes, one with DNMT3A, one
with RAS mutations. Samples of AML blast cells were
grouped according to the major molecular subtypes
(FLT3/TP53/ NPM1) and comprised at least four samples
per molecular genetic combination, with median 84%
blast cells ranging from 25 to 95% (Online Supplementary
Table S1). Both midostaurin and NVP-HDM201 used as
single agent treatment induced varying levels of loss in cell
viability with correlation to certain AML subsets (Figure
2). Data for MOLM-13 and MV4-11 cell lines were includ-
K. Seipel et al.
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Figure 3. Synergistic responses in FLT3-ITD AML blast cells to midostaurin and
HDM201. Cell viability was determined in individual AML patient cells treated
with increasing dosage of NVP-HDM201 as single compound and in combina-
tion treatment with midostaurin (PKC412) in FLT3-ITD/TP53wt/NPM1wt
relapsed AML (patient 13) (A), FLT3-ITD/TP53wt/NPM1wt primary AML (patient
16) (B) and in FLT3-ITD/TP53wt/NPM1mut primary AML (patient 20) (C).
Combination indexes were calculated according to Chou Talalay.42
A
B
C
ed as, compared to primary FLT3-ITD AML cells with
80% blast cells, FLT3-ITD AML cell lines with 100% blast
cells are more susceptible to midostaurin (Figure 2A), and
less susceptible to NVP-HDM201 (Figure 2B). 
With respect to midostaurin, FLT3-ITD/TP53wt NK-
AML cells were distinctly more susceptible than FLT3-
ITD/TP53wt cells. Patient derived AML blast cells charac-
terized by FLT3-ITD/TP53wt/NPM1wt were susceptible
to midostaurin with a median loss of 30% viability after
treatment with 500nM PKC412. 
FLT3-ITD/TP53wt/NPM1wt cells with 11q23/MLL
abnormalities, MOLM-13 (t(9;11) and MV4-11 (t(4;11) lost
60% cell viability within 24 hours when treated with
500nM midostaurin. All other AML cells including 
FLT3-ITD/TP53wt/ NPM1mut, FLT3wt and TP53mut cells
were less susceptible to midostaurin with 0-10% reduced
viability at 500nM midostaurin (Figure 2A). 
With respect to NVP-HDM201, we observed that the
same NK-AML blast cells characterized by FLT3-
ITD/TP53wt/NPM1wt and sensitive to midostaurin were
most susceptible to the MDM2 inhibitor NVP-HDM201,
with a median loss of 45% viability within 24 hours at
100nM NVP-HDM201. MOLM-13 and MV4-11 cells were
less susceptible with a loss of 20% viability at 100nM
NVP-HDM201. FLT3-ITD/TP53wt/NPM1wt cells
responded with a median 20% loss of viability and FLT3-
ITD/TP53wt/NPM1wt with median 10% loss of viability
at 100nM NVP-HDM201. All other AML cells including
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Figure 4. Dose-dependent induction of apoptosis and cell death in FLT3-ITD AML cells. Induction of tumor suppressor protein p53 in MV4-11 (A) and MOLM-13 cells
(B) treated for 24 hours with the indicated amounts of NVP-HDM201 and midostaurin. Relative quantitation of CDKN1A mRNA (C) and MCL-1 mRNA (D) in AML cells
treated for 24 hours with midostaurin (PKC412) (black bars) and NVP-HDM201 (light grey bars) alone or in combination (dark grey bars). Cytometric assays in MV4-
11 AML cells treated with NVP-HDM201 and midostaurin alone and in combination to measure induction of cell death (subG1 fraction) using DAPI staining (E) and
induction of apoptosis using AnnexinV/PI staining (F). 
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FLT3-ITD/TP53wt/NPM1wt and TP53mut cells were
minimally susceptible to NVP-HDM201 with 1-5%
reduced viability when treated with 1 mM compound
(Figure 2B).  
In single agent treatments with 50nM compound, FLT3-
ITD/TP53wt/NPM1wt cells were significantly more sus-
ceptible to midostaurin and NVP-HDM201 than FLT3-
ITD/TP53wt/NPM1mut and FLT3wt cells (Figure 2C,D).
FLT3-ITD/TP53wt/NPM1wt cells lost more than 20% cell
viability within 24hours at 50nM PKC412 while all other
AML cells and normal peripheral blood monocytes were
unaffected by this low dose treatment (Figure 2C).
Similarly, FLT3-ITD/TP53wt/NPM1wt cells lost 30% cell
viability within 24 hours at 50nM NVP-HDM201 while all
other AML cells were significantly less affected by this
low dose treatment and TP53mut AML cells as well as
normal peripheral blood monocytes were unaffected
(Figure 2D). 
These data propose that the ideal target population for
the treatment with midostaurin and NVP-HDM201 are
FLT3-ITD NK-AML cells with a high allelic ratio of FLT3-
ITD that are wild type for TP53 and NPM1. 
Specificity and efficacy of combined HDM201 and
midostaurin against FLT3-ITD/TP53wt/NPM1wt AML
cells
The response of AML cells to 50nM midostaurin in
combination with conventional induction therapy (CI,
20nM cytarabine and 20nM idarubicin) or in combination
with 50nM NVP-HDM201 was determined by in vitro
cytotoxicity assays. Similar to the single agent treatments
reported above, FLT3-ITD/TP53wt NK-AML cells were
most susceptible to the combined treatment whereas
FLT3-ITD/TP53mut cells turned out to be resistant and
FLT3-ITD/TP53wt cells showed intermediate responses
(Figure 2E,F). 
The combination of midostaurin with conventional
induction treatment had significant effects on TP53wt
AML cells with 30-40% median loss of cell viability in
FLT3-ITD cells and 15-25% reduction in FLT3wt cells
exposed to 20nM CI and 50nM midostaurin for 24 hours
(Figure 2E). TP53mut AML cells and normal peripheral
blood monocytes were affected with 5-10% median loss-
es in cell viability. The effects of conventional induction
treatment on cell viability were enhanced by the addition
of midostaurin in FLT3-ITD/TP53wt cells independent of
their NPM1 status (Figure 2E). 
The combination of midostaurin with NVP-HDM201
was as effective as the combination of midostaurin with
standard induction therapy. As in the single agent treat-
ments, FLT3-ITD/TP53wt/NPM1wt cells were most sus-
ceptible to this combination with 40% median loss of cell
viability in 24 hours to 50nM NVP-HDM201 and 50nM
midostaurin (Figure 2F). FLT3-ITD/TP53wt/NPM1mut
and FLT3wt/TP53wt/NPM1wt AML cells were less sus-
ceptible with a median reduction of 20% cell viability in
this combination treatment. FLT3wt/TP53wt/NPM1mut
and TP53mut AML cells as well as normal peripheral
blood monocytes were least affected with 3% median
losses in cell viability. The combination of NVP-HDM201
and midostaurin had synergistic effects on cell survival of
FLT3-ITD positive AML cells with a combination index of
0.63 in the relapsed AML patient #13 (Figure 3A), and
moderate synergistic effects in FLT3-ITD positive primary
AML cells (Figure 3B,C). FLT3-ITD/TP53wt/NPM1wt pri-
mary AML cells (patient #16) were most susceptible to
this combination treatment (Figure 3B) with reduced
responses in FLT3-ITD/TP53wt/NPM1wt (patient#20) pri-
mary AML (Figure 3C). 
To confirm p53 activation in the presence of MDM2
inhibitors we determined the expression levels of the
tumor suppressor protein p53 and of the p53 target genes
CDKN1A and MCL1 in AML cells treated for 24 hours
with single compounds and with combined treatment.
Protein p53 was stabilized and p53 levels were increased
in AML cells treated with 200nM NVP-HDM201, with
three- to eightfold induction in MV4-11, MOLM-13 and
OCI-AML3 cells, while OCI-AML2 cells had a high p53
level with a maximal 20% increase (Figure 4 A, B, C, D).
CDKN1A gene expression was significantly induced in
FLT3-ITD/TP53wt/NPM1wt AML cells (MOLM-13,
MV4-11, patient#13) and in FLT3wt/TP53wt/NPM1wt
cells (OCI-AML2) treated with 50nM NVP-HDM201
(Figure 4E), and in FLT3wt/TP53wt/NPM1mut cells (OCI-
AML3) treated with 500nM NVP-HDM201, but not in
FLT3wt/TP53mut cells (MOLM-16). To reach the same
level of p53 target gene expression induced by 50nM NVP-
HDM201 in FLT3-ITD/NPM1wt (MOLM-13, MV4-11,
pat#13) and FLT3wt/NPM1wt (OCI-AML2) cells, ten
times more MDM2 inhibitor was required in
FLT3wt/NPM1mut (OCI-AML3) cells. Yoshimoto et al.
2009 showed that FLT3-ITD up-regulates the apoptosis
inhibitor MCL-1 to promote survival of stem cells in acute
myeloid leukemia. They analyzed the function of MCL-1
in FLT3-ITD AML and showed that the enforced expres-
sion of MCL-1 prevented MV4-11 cells from apoptosis in
the presence of 100nM midostaurin. Inhibition of MCL-1
by shRNA resulted in apoptosis of MV4-11 cells. To eluci-
date the mechanism of apoptosis induction by NVP-
HDM201 and midostaurin we analyzed MCL-1 expres-
sion in a variety of AML cells (Figure 4F). MCL-1 gene
expression was repressed in the presence of 50nM 
NVP-HDM201 or 50nM midostaurin in 
FLT3-ITD/TP53wt/NPM1wt AML cells (MOLM-13,
MV4-11, patient#13), with enhanced effects in the combi-
nation treatments. MCL-1 gene expression was repressed
in the presence of 50nM NVP-HDM201 in
FLT3wt/TP53wt/NPM1wt cells (OCI-AML2) and by
500nM NVP-HDM201 in FLT3wt/TP53wt/NPM1mut
cells (OCI-AML3), but not by midostaurin. There was no
repression of MCL-1 gene expression in FLT3wt/TP53mut
cells (MOLM-16). In the susceptible FLT3-ITD cell lines
MV4-11 and MOLM-13 as well as in the relapsed FLT3-
ITD AML sample (patient#13) both compounds led to a
significant reduction in MCL-1 gene expression with
enhanced reduction in the combination treatments (Figure
4F). The effect of NVP-HDM201 and midostaurin treat-
ment on MCL-1 gene repression appeared to be strongly
synergistic with a combination index of 0.25. To further
assess pro-apoptotic effects in AML cells treated with
midostaurin and with the MDM2 inhibitor NVP-
HDM201, cells were stained with AnnexinV and DAPI
and analyzed on a cell imager. Apoptosis and cell death
were induced in FLT3-ITD/TP53wt/NPM1wt cells in a
dose dependent manner by both inhibitors in single com-
pound and combination treatments. There was a signifi-
cant increase in dead cells with subG1 DNA content, and
a concomitant loss of cells in defined cell cycle stages,
most prominently a reduction of cells with G0/G1 phase
DNA content, but also of cells with S-phase and G2 phase
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content in MV4-11 cells treated with 20nM PKC412 and
50nM NVP-HDM201 (Figure 4G). Moreover, there was a
significant increase in the number of AnnexinV positive
apoptotic cells and a concomitant reduction in AnnexinV
negative non-apoptotic cells in MV4-11 cells treated with
20nM PKC412 and 50nM NVP-HDM201 (Figure 4H). The
pro-apoptotic and lethal effects of the single compound
treatments were enhanced in the combined treatments
with a combination index of 0.44 indicating synergistic
pro-apoptotic and lethal effects with NVP-HDM201 and
midostaurin. A similar induction of apoptosis and cell
death was also detected in MOLM-13 cells treated with
20nM PKC412 and 50nM NVP-HDM201 (Online
Supplementary Figure S2). While there was no pro-apoptot-
ic effect in FLT3wt/TP53wt/NPM1mut (OCI-AML3) and
FLT3-ITD/TP53mut (PL-21) cells at 100nM compounds, a
low-level induction of apoptosis and cell death was
detected in OCI-AML3 and PL-21 cells after 24 hours of
treatment with 1 mM compounds (data not shown). 
In summary, our data indicate that NVP-HDM201 and
midostaurin can induce apoptosis and cell death effective-
ly and specifically in FLT3-ITD/TP53wt/NPM1wt AML
cells. FLT3-ITD is a constitutively active growth factor
receptor signaling via PI3K-AKT,13 via RAS-MEK-ERK13
and via STAT514,15 leading to cell growth and proliferation
via p53 inhibition and MCL1 induction (Figure 5). We
have shown that MDM2 inhibition by NVP-HDM201 can
reactivate p53 function leading to induction of CDKN1A
and inhibition of MCL1 gene expression. Inhibition of
FLT3-ITD by midostaurin, however, did not restore p53
function, but led to reduced MCL1 gene expression via
RAS-MEK-ERK and/or STAT5 signaling (Figure 5). These
data suggest that the combined use of NVP-HDM201 and
midostaurin might be a promising treatment option par-
ticularly in FLT3-ITD AML relapsed or refractory to con-
ventional therapy. 
Discussion
Acute myeloid leukemia (AML) characterized by nor-
mal karyotype (NK) and presence of the mutated FLT3
growth factor receptor gene variant FLT3-ITD comprises
27-34% of newly diagnosed AML. The subset of NK-AML
patients with high allelic ratio of FLT3-ITD (>0.5) and
NPM1 wild type is associated with adverse risk and low-
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Figure 5. Schematic representation of the FLT3-ITD signaling
pathways and downstream effects. FLT3-ITD is a constitutively
active growth factor receptor signaling via PI3K-AKT, via RAS-MEK-
ERK and via STAT5 leading to cell growth and proliferation via p53
inhibition and MCL1 induction. p53 function can be reactivated by
NVP-HDM201 treatment leading to induction of CDKN1A and inhi-
bition of MCL1 gene expression. MCL1 gene expression can be
inhibited by NVP-HDM201 via p53 induction and by midostaurin
(PKC412) via RAS-MEK-ERK and/or STAT5 signaling.  
est survival rates. Survival rates are higher in NK-AML
patients with high allelic ratio of FLT3-ITD and NPM1mut
or low allelic ratio of FLT3-ITD and NPM1 wild type or
FLT3wt and NPM1mut which have all been classified as
intermediate risk.16 The leukemic cells of all these AML
subsets have substantially elevated levels of cellular p53
antagonists and reduced p53 activity17 which identifies
them as targets for treatments aiming to restore p53 func-
tion including conventional chemotherapy with genotoxic
compounds and non-genotoxic treatments with p53 reac-
tivating compounds. 
MDM2 is an established cellular p53 antagonist fre-
quently overexpressed in AML cells.  A variety of MDM2
inhibitors have been developed and tested in AML cell
lines. Compounds currently in clinical trials for the treat-
ment of AML include idasanutlin (RG7388), NVP-
CGM097 and NVP-HDM201.12,18,19 We have studied the
MDM2 inhibitor idasanutlin in combination with the
MEK inhibitor cobimetinib in AML cell lines and patient
samples and found this combination to be effective only
in AML cells expressing high levels of FLT3 and MDM2
protein.20 The activity of NVP-CGM097 was investigated
in AML cell lines and primary AML cells expressing wild
type and mutant p53, alone and in combination with the
FLT3 inhibitor PKC412 (midostaurin) or the MEK
inhibitor AZD 6244.19 Synergy was observed when NVP-
CGM097 was combined with FLT3 inhibition against
oncogenic FLT3 expressing cells, as well as when com-
bined with MEK inhibition in cells with activated MAPK
signalling. In addition to reactivating p53 in AML cells by
specific MDM2 inhibition the FLT3 receptor can be
directly targeted by (more or less) specific tyrosine kinase
inhibitors.5,21 
In the present study, we tested a variety of FLT3 and
MDM2 inhibitors.  The effects on cell survival of FLT3-
ITD AML cells were consistent for the FLT3 inhibitors
midostaurin (PKC412), quizartinib (ACC220) and gilteri-
tinib (ASP2215), but varied for the MDM2 inhibitors
idasanutlin (RG7388), NVP-CGM097 and NVP-HDM201.
The most potent MDM2 inhibitor NVP-HDM201 exhibit-
ed superior combinatory effects on cell viability of FLT3-
ITD AML cells together with midostaurin, and moderate
combinatory effects together with quizartinib and gilteri-
tinib. The different combinatory potentials may be related
to the target specificity of the three FLT3 inhibitors. While
quizartinib (ACC220) inhibits FLT3 and PDGFR kinases,22
gilteritinib (ASP2215) inhibits FLT3, LTK, ALK, and AXL
kinases,8 and midostaurin (PKC412) inhibits FLT3, KIT,
PKC, PPK, VEGFR-2, PDGFR, and SYK kinases.23 PDGFR
and VEGFR-2 are expressed in the bone marrow of AML
patients24,25 and, like FLT3, signal via PI3K/AKT and
MDM2 to inhibit p53.26,27 The stem cell growth factor
receptor KIT is expressed in the bone marrow and, like
FLT3-ITD, signals via PI3K/AKT and MDM2 to inhibit
p53, and via JAK2 and STAT5.28
MOLM-13 and MV4-11 AML cells were most suscepti-
ble to the FLT3 inhibitor midostaurin. Both cell lines have
a high allelic ratio of FLT3-ITD and harbor MLL rearrange-
ments, created by t(9;11) and t(4;11), encoding MLL-AF9
and MLL-ENL, respectively. FLT3 and MLL cooperate in
AML29 and leukemic cells with mutations in FLT3 and
MLL are known to be susceptible to midostaurin.30,31 In the
absence of MLL mutations, FLT3-ITD AML cells were less
susceptible to midostaurin, but more susceptible to NVP-
HDM201 indicating that the presence of MLL fusion pro-
teins may change the susceptibility of AML cells to FLT3
and MDM2 inhibitors. 
NK-AML cells with FLT3-ITD/TP53wt/NPM1wt were
particularly susceptible to the combination of midostaurin
with conventional induction therapy or with NVP-
HDM201. In contrast, NK-AML cells with mutated TP53
were rather resistant to midostaurin and NVP-HDM201,
and they have previously been shown to be resistant to
chemotherapy with genotoxic compounds32 and to other
MDM2 inhibitors.33 As both the conventional induction
therapy and MDM2 inhibition induce cell cycle exit and
apoptosis via p53 activation, these treatments can only be
effective in a TP53wild type context.9 The presence of one
mutated TP53 allele may be sufficient to suppress the
function of the remaining p53 wild type protein. Hence,
restoring wild-type p53 activity may be a promising
option for treatment of AML with mutated TP53.34 HL-60
cells with deleted TP53 were resistant to midostaurin and
HDM201, indicating that these two compounds specifi-
cally target AML cells with functional p53 protein. This is
in apparent contrast to the FLT3- inhibitor sorafenib and
the MDM2 inhibitor nutlin-3 which promoted synergistic
cytotoxicity irrespectively of FLT3 and p53 status via
induction of the pro-apoptotic Bcl-2 family members Bax
and Bak in p53 wild type and p53 deleted cells.35
It seems remarkable that FLT3wt/TP53wt/NPM1mut
AML cells turned out to be as refractory to midostaurin
and NVP-HDM201 as TP53mut cells. This suggests that
the presence of mutated NPM1 protein is sufficient to pre-
vent induction of p53 target genes by midostaurin or NPV-
HDM201 in these cells. The mutated NPM1 protein
(NPM1c) reduces the susceptibility of FLT3-ITD AML cells
to both midostaurin and NVP-HDM201, indicating that
the same molecular mechanisms may be involved in
FLT3wt and FLT3-ITD cells. NPM1c is exported to the
cytoplasm36 where it inhibits the tumor suppressor protein
p53 by cytoplasmic retention. This leads to reduction of
p53 protein in the nucleus and decreases its stability and
transcriptional activation function.37 It appears that this
loss of p53 activity by NPM1c cannot be compensated by
inhibition of MDM2 or FLT3, at least not with NVP-
HDM201 or midostaurin. In contrast, nutlin-3 can induce
apoptosis and cell death in FLT3wt/TP53wt/NPM1mut
cells,17 indicating a fundamental difference in the activities
of the two MDM2 inhibitors. 
The molecular mechanisms involved in p53 activation
appear to be different in the conventional induction treat-
ment. Here, FLT3wt/TP53wt/NPM1mut AML cells were
more susceptible to conventional induction treatment
than TP53mut cells, indicating that the presence of
NPM1c is not sufficient to prevent p53 activation by geno-
toxic substances.  This may be reflected by the usually
favorable outcome of FLT3wt/TP53wt/NPM1mut AML
patients after standard induction treatment.38,39
Midostaurin can enhance effects of conventional induc-
tion therapy in FLT3-ITD cells in vitro and in vivo. As eval-
uated in a randomized, double-blind, phase III interna-
tional study (clinicaltrials.gov identifier 00651261) in high-
risk patients with newly diagnosed, FLT3-mutant AML
(CALGB10603/RATIFY trial), the multikinase inhibitor
midostaurin plus standard chemotherapy improved sur-
vival compared with placebo plus chemotherapy.40,41 On
April 28, 2017, the U.S. Food and Drug Administration
approved midostaurin (RYDAPT, Novartis
Pharmaceuticals Corp.) for the treatment of adult patients
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with newly diagnosed acute myeloid leukemia (AML)
who are FLT3 mutation-positive (FLT3+), in combination
with standard cytarabine and daunorubicin induction and
cytarabine consolidation. This combination therapy is,
however, not suitable for NK AML patients with 
FLT3-ITD in relapse or refractory to conventional induc-
tion treatment or unfit for intensive treatment. For the
subset of AML patients with a high ratio of FLT3-ITD and
adverse prognosis, the combined use of non-genotoxic tar-
geted compounds, such as the combination of midostau-
rin and NVP-HDM201, may represent a promising treat-
ment option. Synergistic effects on cell viability with
midostaurin and NVP-HDM201 were observed independ-
ent of sequence of application, indicating that the order of
target inhibition for FLT3 and MDM2 was not important.
Sequential application of NVP-HDM201 and midostaurin
had the same effects on cell viability as direct combination
treatment.  Pretreatment with one inhibitor did not
enhance the susceptibility of AML cells to the second
inhibitor. This leaves several options for treatment regi-
mens in a prospective clinical trial. The best therapy regi-
men in combination treatments with midostaurin and
NVP-HDM201 for AML patients will have to be defined
empirically. 
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